Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab

Primary cutaneous apocrine carcinoma (PCAC) is a rare and highly aggressive cutaneous adnexal type of tumor that has a high metastasis rate and a poor prognosis. Although there are several case reports describing the successful treatment of PCAC with chemoradiotherapy or molecular targeting therapy,...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2017-01, Vol.10 (1), p.52-56
Main Authors: Furudate, Sadanori, Fujimura, Taku, Tsukada, Akira, Sato, Yota, Hidaka, Takanori, Tanita, Kayo, Kambayashi, Yumi, Haga, Takahiro, Hashimoto, Akira, Aiba, Setsuya
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
Case Report
Case reports
Chemoradiotherapy
Chemotherapy
Denosumab
Epidermal growth factor
Gene amplification
Immunotherapy
Ligands
Lymphatic system
Metastasis
Monoclonal antibodies
NMR
Nuclear magnetic resonance
Primary cutaneous apocrine carcinoma
Radiation therapy
RANKL
Targeted cancer therapy
Tumor microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary cutaneous apocrine carcinoma (PCAC) is a rare and highly aggressive cutaneous adnexal type of tumor that has a high metastasis rate and a poor prognosis. Although there are several case reports describing the successful treatment of PCAC with chemoradiotherapy or molecular targeting therapy, no standard therapy for the treatment of advanced PCAC has been established yet. Since receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed in cancers of apocrine origin, leading to immunosuppression at the tumor site, we hypothesized that targeting RANKL with denosumab might be useful for the treatment of PCAC. In this report, we describe a case with advanced PCAC on the scrotum successfully treated with systemic chemotherapy using carboplatin and paclitaxel, and radiotherapy followed by denosumab.
ISSN:1662-6575
1662-6575
DOI:10.1159/000455091